* Precision BioSciences Inc DTIL.OQ DTIL.O is expected
to show
a fall in quarterly revenue when it reports results on May 13
for the period ending March 31 2024
* The Durham North Carolina-based company is expected to
report a
31.4% decrease in revenue to $6.021 million from $8.78 million a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Precision BioSciences
Inc is
for a loss of $1.91 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.
* Wall Street's median 12-month price target for Precision
BioSciences Inc is $30.00, above its last closing price
of $10.93.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -3.99 -2.05 -4.06 Missed -98.3
Sep. 30 2023 -5.03 -4.87 -2.10 Beat 56.9
Jun. 30 2023 -7.52 -7.32 -3.00 Beat 59
Mar. 31 2023 -6.80 -6.78 -6.90 Missed -1.8
Dec. -6.48 -6.22 -7.80 Missed -25.3
31 2022
Sep. 30 2022 -7.63 -7.95 -6.60 Beat 17
Jun. 30 2022 -12.38 -12.33 -13.80 Missed -11.9
Mar. 31 2022 -16.01 -16.23 -13.80 Beat 15
This summary was machine generated May 10 at 13:42 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)